| Literature DB >> 10972374 |
H Van den Hout, A J Reuser, A G Vulto, M C Loonen, A Cromme-Dijkhuis, A T Van der Ploeg.
Abstract
Pompe's disease is a fatal muscular disorder caused by lysosomal alpha-glucosidase deficiency. In an open-label study, four babies with characteristic cardiomyopathy were treated with recombinant human alpha-glucosidase (rhGAA) from rabbit milk at starting doses of 15 mg/kg or 20 mg/kg, and later 40 mg/kg. The enzyme was generally well tolerated. Activity of alpha-glucosidase normalised in muscle. Tissue morphology and motor and cardiac function improved. The left-ventricular-mass index decreased significantly. We recommend early treatment. Long-term effects are being studied.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10972374 DOI: 10.1016/s0140-6736(00)02533-2
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321